Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised control trial - SEV-Covid Trial

AIIMS Rishikesh0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Age >=18 years at time of participation in the study
•2.Laboratory (RT-PCR) confirmed infection with 2019-nCoV
•3.Willingness of study participant to accept randomization to any assigned treatment arm
•4.Must agree not to enrol in another study of an investigational agent prior to completion of the present study

•1.Use of medications that are contraindicated with lopinavir/ritonavir, Hydroxychloroquine/ Chloroquine and that cannot be replaced or stopped
•4.Physicianâ??s decision that participation in the trial is not in patientsâ?? best interest, or any condition that does not allow the protocol to be followed safely
•5.Patient already on antiretroviral therapy with Lopinavir-Ritonavir based regimen or on Hydroxychloroquine/Chloroquine
•6.Any known contraindication to test drugs such as retinopathy and QT prolongation
•7.Known allergic reaction to Lopinavir-ritonavir, Hydroxychloroquine/ Chloroquine
•8.Pregnant or breastfeeding females
•9.Receipt of any experimental treatment for 2019-nCoV (off-label, compassionate use, or trial related) within 30 days prior to participation in the present study

发起方